Market Currents
The Supreme Court will review a "pay for delay" case in which Solvay, now owned by Abbott Labs...
-
Sunday, December 9, 2012, 2:27 AM ETThe Supreme Court will review a "pay for delay" case in which Solvay, now owned by Abbott Labs (ABT), paid three generic drug companies to up to $40M a year, including Watson (WPI), to postpone making copycat versions of Solvay's Androgel testosterone treatment. The case has industry wide ramifications, with the FTC saying the practice costs customers $3.5B a year. (previous)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
This news story has 1 comment:
Two comments - One, I hope Abbott loses. This is just plain wrong.
Two, This shows just how screwed up our medical system is.
Three, There obviously needs to be more generic producers. Perhaps a few of these large generic producers need to be broken up if the industry is basically an oligopoly. Break up one.
Getting paid to not compete just comes across as a bribe.